PMC:7600245 / 14523-14684 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T48","span":{"begin":96,"end":104},"obj":"Disease"},{"id":"T49","span":{"begin":108,"end":120},"obj":"Disease"}],"attributes":[{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0020502"}],"text":"The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T121","span":{"begin":57,"end":63},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T122","span":{"begin":67,"end":68},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T140","span":{"begin":4,"end":8},"obj":"Chemical"}],"attributes":[{"id":"A140","pred":"chebi_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T4","span":{"begin":115,"end":120},"obj":"Phenotype"}],"attributes":[{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0001945"}],"text":"The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S."}

{"project":"LitCovid-sentences","denotations":[{"id":"T106","span":{"begin":0,"end":161},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S."}

{"project":"LitCovid-PubTator","denotations":[{"id":"350","span":{"begin":96,"end":104},"obj":"Disease"},{"id":"351","span":{"begin":115,"end":120},"obj":"Disease"}],"attributes":[{"id":"A350","pred":"tao:has_database_id","subj":"350","obj":"MESH:C000657245"},{"id":"A351","pred":"tao:has_database_id","subj":"351","obj":"MESH:D005334"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The drug is being developed by BioCryst, U.S., and being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S."}